KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Liabilities: 2009-2025

Historic Total Liabilities for Neogenomics (NEO) over the last 16 years, with Sep 2025 value amounting to $536.5 million.

  • Neogenomics' Total Liabilities fell 26.80% to $536.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.5 million, marking a year-over-year decrease of 26.80%. This contributed to the annual value of $735.7 million for FY2024, which is 0.54% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Total Liabilities is $536.5 million, which was down 0.63% from $539.9 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Total Liabilities peaked at $769.1 million during Q3 2021, and registered a low of $536.5 million during Q3 2025.
  • Its 3-year average for Total Liabilities is $695.1 million, with a median of $730.8 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 186.39% in 2021, then declined by 26.80% in 2025.
  • Neogenomics' Total Liabilities (Quarterly) stood at $761.5 million in 2021, then declined by 2.56% to $742.0 million in 2022, then dropped by 0.31% to $739.7 million in 2023, then declined by 0.54% to $735.7 million in 2024, then declined by 26.80% to $536.5 million in 2025.
  • Its last three reported values are $536.5 million in Q3 2025, $539.9 million for Q2 2025, and $713.2 million during Q1 2025.